- ISIN
- US05360L2051
- CUSIP
- 05360L205
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 27, 2017
Highlights
- Market Cap
- $824.73K
- Enterprise Value
- -$1.59M
- EPS (TTM)
- -$0.55
- Total Revenue (TTM)
- $1.40M
- EBITDA (TTM)
- -$2.06M
- Year Range
- $0.15 - $0.97
- Target Price
- $12.00
- ROA (TTM)
- -70.99%
- ROE (TTM)
- -146.24%
- Avg. Volume (1M)
- 3K
- Avg. Volume Value (1M)
- $1.04K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ATXI Performance Chart
Avenue Therapeutics, Inc. (ATXI) is down 43.0% since the beginning of the year. At $0 per share, ATXI is trading 60.0% below its 52-week high of $1. Investors who bought $1,000 worth of ATXI shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Avenue Therapeutics, Inc. (ATXI) has returned -43.00% so far this year and -15.72% over the past 12 months.
Avenue Therapeutics, Inc.
- 1D
- 0.00%
- 1M
- 27.11%
- 6M
- 91.93%
- YTD
- -43.00%
- 1Y
- -15.72%
- 3Y*
- -82.88%
- 5Y*
- -81.93%
- 10Y*
- —
- ALL TIME*
- -66.71%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ATXI Monthly Returns History
Based on dividend-adjusted daily data since Jun 27, 2017, ATXI's average daily return is -0.05%, while the average monthly return is -2.80%.
Historically, 36% of months were positive and 64% were negative. The best month was Sep 2022 with a return of +179.1%, while the worst month was Oct 2022 at -76.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 12 months.
On a daily basis, ATXI closed higher 43% of trading days. The best single day was Sep 27, 2022 with a return of +106.3%, while the worst single day was Oct 12, 2020 at -59.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -70.30% | -5.94% | 52.63% | 89.66% | -45.45% | -6.67% | 38.46% | -43.00% | |||||
| 2025 | -32.00% | -19.12% | -72.73% | -19.72% | -9.55% | -7.87% | 126.71% | 25.27% | 38.05% | -8.50% | 6.19% | -11.03% | -65.99% |
| 2024 | -8.07% | 2.50% | -2.77% | -54.71% | -31.34% | 1.74% | -20.00% | -9.29% | -1.97% | -3.61% | -10.58% | -6.80% | -83.44% |
| 2023 | 18.97% | -19.57% | 4.95% | -18.46% | 14.22% | 7.83% | -10.26% | -26.10% | -8.89% | -66.76% | -9.79% | -24.06% | -86.12% |
| 2022 | -19.47% | -53.51% | 41.66% | -23.22% | -24.26% | -3.82% | -4.79% | -6.08% | 179.07% | -76.29% | -43.93% | -13.43% | -91.48% |
| 2021 | -0.50% | -20.61% | 29.15% | -15.65% | -3.13% | -49.40% | -28.69% | 1.12% | -17.68% | 6.04% | -10.76% | -35.60% | -84.74% |
Benchmark Metrics
Avenue Therapeutics, Inc. has an annualized alpha of -16.51%, beta of 0.41, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since June 27, 2017.
- This stock participated in 213.57% of S&P 500 Index downside but only -98.78% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.41 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -16.51%
- Beta
- 0.41
- R²
- 0.00
- Upside Capture
- -98.78%
- Downside Capture
- 213.57%
Return for Risk
Risk / Return Rank
ATXI ranks 52 for risk / return — above 52% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Avenue Therapeutics, Inc. (ATXI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ATXI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.49 | ||
| Sortino ratioReturn per unit of downside risk | -0.54 | ||
| Omega ratioGain probability vs. loss probability | 1.21 | 1.25 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | -0.18 | 2.00 | -2.18 |
| Martin ratioReturn relative to average drawdown | -0.30 | 8.49 | -8.79 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Avenue Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Avenue Therapeutics, Inc. was 100.00%, occurring on Feb 11, 2026. The portfolio has not yet recovered.
The current Avenue Therapeutics, Inc. drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Feb 2026 | 5y 5mo | — | 5y 10moSep 2020 - now | — |
-74.55%Oct 2018 | 1y 3mo | 1y 2mo | 2y 6moJun 2017 - Dec 2019 | Rate-hike selloffLate 2018 |
-43.11%Mar 2020 | 1mo 6d | 2mo 12d | 3mo 18dFeb 2020 - May 2020 | COVID crash2020 |
-18.31%Jul 2020 | 1mo 12d | 1mo 6d | 2mo 18dJun 2020 - Aug 2020 | — |
-11.46%Jan 2020 | 13d | 13d | 26dJan 2020 - Jan 2020 | — |
Drawdown Indicators
| ATXI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -83.80% | -9.10% | -74.70% |
Max Drawdown (3Y)Largest decline over 3 years | -99.82% | -18.90% | -80.92% |
Max Drawdown (5Y)Largest decline over 5 years | -99.99% | -25.43% | -74.56% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -71.15% | -10.70% | -60.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 49.63% | 2.14% | +47.49% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Avenue Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Avenue Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ATXI relative to other companies in the Biotechnology industry. Currently, ATXI has a P/S ratio of 0.9. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ATXI in comparison with other companies in the Biotechnology industry. Currently, ATXI has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ATXI
Add Avenue Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ATXI